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Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid 
metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is 
upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 
deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to 
explore the potential mechanisms involved. 
 
Methods 
We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes 
exclusively in cardiomyocytes to generate an experimental mouse model with 
conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). 
 
Findings 
Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1-/-) have a normal cardiac function 
combined with a favorable metabolic phenotype against HFD-induced glucose 
intolerance and obesity. Glucose intolerance protection was linked to higher hepatic 
fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy 
expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-
atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. 
cm-Lrp1-/- mice showed ANP signaling activation that was linked to increased fatty acid 
(FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide 
receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic 
protection in cm-Lrp1-/- mice.  
 
Conclusions 
These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels 
modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism. 
 
 















Nonstandard Abbreviations and Acronyms 
ACC  Acetyl-CoA carboxylase 
Akt  Protein Kinase B 
AMPK  AMP-activated protein kinase 
ANP  Atrial natriuretic peptide 
AUC  Area under the curve 
BAT  Brown adipose tissue 
BSA  Phosphate buffered saline 
BNP  Brain natriuretic peptide 
CE  Cholesteryl esters 
cGMP  Cyclic guanosine monophosphate 
CLAMS Comprehensive lab animal monitoring system  
CPT1  Carnitine palmitoyltransferase I 
DAPI  4',6-diamidino-2-phenylindole 
eWAT  Epididymal fat 
FA  Fatty acid 
FAO  Fatty acid oxidation 
FASP  Filter Aided Sample Preparation  
FC  Free cholesterol 
FFA  Free fatty acid 
GDF15 Growth and differentiation factor 15 
GLUT  Glucose transporter 
GTT  Glucose tolerance test 
HDL  High density lipoprotein 
HF  Heart failure 
HFD  High fat diet 
IR  Insulin resistance 
LDLR  Low density lipoprotein receptor 
LIPG  Endothelial lipase 
LpL  Lipoprotein lipase 
LRP1  Low-density lipoprotein receptor-related protein 1 
LV  left ventricle 
LVAWd LV anterior wall at end cardiac diastole 
LVEDV  LV end-diastolic volume 
LVEF  LV ejection fraction 
LVESV LV end-systolic volume 














LVIDd  LV internal diameter diastole 
LVIDs  LV internal diameter systole 
LVPWd LV posterior wall at end cardiac diastole 
NP  Natriuretic peptide 
NPR-A Natriuretic peptide receptor A 
NPR-C Natriuretic peptide receptor C 
OFG  Oral fat gavage 
 Mitochondrial Oxidative Phosphorylation System 
pAMPK Phosphorylated AMP-activated protein kinase 
pNpp  p-nitrophenyl phosphate 
Pro-ANP Pro-atrial natriuretic peptide 
Pro-BNP Pro-brain natriuretic peptide 
pVASP Phosphorylated VASP 
q-RT-PCR Quantitative real-time reverse transcriptase-polymerase chain reaction 
RER  Respiratory exchange ratio 
SCX  Strong Cation Exchange 
TG  Triglyceride 
TLC  Thin layer chromatography 
TMT  Tandem mass tags 
TnT  Troponin T 
UCP3  Mitochondrial uncoupling protein 3 
VASP  Vasodilator-stimulated phosphoprotein 
VCO2  CO2 production 
VO2  Oxygen consumption 
VLDLR Very low-density lipoprotein receptor 


















The metabolic syndrome preceding type 2 diabetes is mainly caused by an inefficient 
coordination of energy utilization by key organs [1]. It is known that alterations in fatty 
acid (FA) metabolism play a crucial role in inter-organ dyscoordination and insulin 
resistance (IR) [2]. Further, in metabolic diseases, the heart shows an exacerbated 
uptake of free FAs (FFAs) [3] and lipoproteins [4] underlying neutral lipid accumulation 
in cardiomyocytes. 
The low-density lipoprotein receptor-related protein 1 (LRP1) is a key receptor that 
modulates energy utilization by different tissues. LRP1 is both a carrier and a signaling 
receptor that regulates processes related with lipid metabolism and glucose 
homeostasis [5,6]. In the hallmark of lipid metabolism, LRP1 is involved in the uptake 
of unmodified and modified lipoproteins in different tissues causing alterations in the 
lipid content, generally associated with dyslipemic conditions. LRP1 is involved in the 
lipid transport from lipoproteins to hepatocytes [5], coronary vascular smooth muscle 
cells [7,8], cardiomyocytes [9,10] and adipocytes [11]. Specifically, adipocyte LRP1 
modulates not only lipid transport but also glucose homeostasis through the control of 
insulin sensitivity and energy expenditure [11]. In the context of glucose homeostasis, 
LRP1 has a regulatory action on the insulin receptor and GLUT4 activation in different 
tissues and organs including the brain [12,13]. Interestingly, insulin favors LRP1 
translocation to the cell membrane in the liver, increasing thus postprandial lipoprotein 
uptake [14]. Recently, it has been shown that hepatic LRP1 protects against IR and 
hepatic steatosis [13,15]. 
The liver plays a central role in the regulation of metabolism, receiving signals from 
multiple organs such as the pancreatic islets, the central nervous system, adipose 
tissue and kidneys [16]. It has also been suggested that the heart may also exert 
control over the metabolism of peripheral organs through the secretion of certain 
molecules called cardiokines. These cardiokines can affect the metabolic function of 
various cell types influencing whole-body homeostasis [17–19]. However, it is unknown 
at this moment whether lrp1 in cardiomyocytes modulates the production and release 
of cardiokines potentially involved in whole-body metabolism. The objectives of this 
study have been to 1) generate a murine experimental model of conditional Lrp1 
deficiency in cardiomyocytes by using the TnT-iCre transgenic mice with thoroughly 
tested suitability to delete genes exclusively in cardiomyocytes [20]; 2) study the impact 
of cardiomyocyte Lrp1 deficiency in whole-body metabolism; 3) analyze the differential 














differential proteins, in particular of cardiokines, on target-tissue fatty acid uptake and 
metabolism. 
 
2. Material and methods 
cm-Lrp1-/- transgenic mice generation and characterization 
We generated an experimental mouse model with conditional and cardiomyocyte-
specific Lrp1 deficiency (TNT-iCre+-LRP1flox/flox or cm-Lrp1+/+) by treatment with 
doxycycline [20]. The specific controls for this animal model are TNT-iCre--Lrp1flox/flox or 
cm-Lrp1-/-. The generation of cm-Lrp1-/- transgenic mice is described in online Figure 
S1. To achieve cardiomyocyte-specific LRP1 inactivation, we use a cardiomyocyte-
specific Cre deletor and a floxed allele of Lrp1. We crossed commercial LRP1flox/flox 
mice (B6;129S7-Lrp1tm2Her/J; stock: #012604, Jackson Laboratories) carrying loxP sites 
within the LRP1 gene with TNT-iCre transgenic mice (kindly provided by Prof. Bin 
Zhou, Albert Einstein College of Medicine, USA) [20], for eight generations (Figure 1A). 
Transgenic founder mice were genotyped by PCR analysis on tail tip genomic DNA 
using primers for LRP1, Cre and Nrt (Figure 1B). Genomic DNA was extracted with a 
Wizard® SV Genomic DNA Purification System (Promega, Madison, WI, USA) and 
PCR analysis was performed with oligonucleotides synthesized by IDT (Integrated 
DNA Technologies, Inc; Coralville, IA, USA), using an Expand High Fidelity PCR 
System (Roche Molecular Systems). The oligonucleotides used are specified in Table 
S1.  
Mice were housed in specific pathogen-free facilities with a 12-hour light/12-hour dark 
cycle. Both groups, ten-week-old males cm-Lrp1+/+ and cm-Lrp1-/-, were treated daily 
with doxycycline cyclate (Sigma-Aldrich) (Dox) through their drinking water (1.5 
mg/mL/kg) ad libitum to assess the conditional Lrp1 inhibition in cardiomyocytes. The 
control group (cm-Lrp1+/+) was also treated with Dox to avoid interference with the 
treatment. Robertson et al., showed that Dox has a long half-life [21]. 
In the first experimental setting (online Figure S1A), after checking cardiac function, 
cm-Lrp1+/+ and cm-Lrp1-/- ten-week-old mice were fed high-fat cholesterol-containing 
diet (HFD TD.88137; Harlan Teklad) for six weeks. In the second experimental setting, 
cm-Lrp1+/+ and cm-Lrp1-/- ten-week-old mice were randomized to placebo (PBS) or to 
NPRA antagonist (A71915, 200 g/Kg in PBS, volume 100 uL) treatment during the 6 
weeks on HFD (online Figure S1B). Age-matched littermates were used for all 
experiments and at least 6 mice per group were analyzed considering α=0.05, 














Blood samples were taken in fasting conditions in the fourth week (150 l) and after 
sacrificing (400 L). The serum was frozen at -20ºC and used to measure glucose, 
insulin and lipid levels. The mice were euthanized at week six and samples from liver, 
skeletal muscle, heart, epididymal fat (eWAT), and brown adipose tissue (BAT), were 
kept frozen at -80ºC for lipid and molecular analysis. A piece of these tissues was also 
embedded in OCT for immunohistochemistry. All experimental protocols were 
approved by the Institutional Animal Care and Use Committees at the Research 
Institute (IR)-Sant Pau, and complied with all guidelines concerning the use of animals 
in research and teaching as defined by the Guide for the Care and Use of Laboratory 
Animals (NIH Publication Nº.80-23, revised 1996). 
Biochemical analysis 
Insulin serum levels were measured using a Mouse Insulin ELISA (Mercodia) following 
the manufacturer’s instructions. The HOMA index, an estimation of insulin resistance, 
was calculated as: [fasting serum insulin (ng/ml) x fasting serum glucose (mM)]/22.5. 
Serum lipids and lipoproteins, including cholesterol, triglyceride (TG) (corrected from 
free glycerol), phospholipids, FFAs, high density lipoprotein (HDL) cholesterol and 
phospholipids, were enzymatically determined using commercial kits adapted to a 
COBAS 6000 autoanalyzer (Roche Diagnostics) [22]. 
 
Analysis of ventricular function 
Transthoracic echocardiography was conducted under light sedation (1% isoflurane in 
oxygen) three days after starting doxycycline treatment (baseline). A second 
echocardiography was conducted six weeks later, at the end of the experimental 
procedure [23]. Standard functional parameters were measured, including left ventricle 
(LV) internal diameter diastole (LVIDd) and LV internal diameter systole (LVIDs), LV 
end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection fraction 
(LVEF), LV fractional shortening (LVFS), LV anterior wall at end cardiac diastole 
(LVAWd), LV posterior wall at end cardiac diastole (LVPWd), and heart rate. 
 
Glucose tolerance test (GTT)  
The glucose tolerance test (GTT) was performed at week six of the dietetic intervention 
in fasting conditions. Basal blood glucose levels were measured from a tail nick 
through ACCU-CHEK® Aviva glucometer (Roche Molecular Systems). The mice were 
then intraperitoneally injected with glucose (1.3mg/g BW). Blood glucose was 














curve (AUC) of the response curve was then calculated using the software Prism 4.0 
[24]. 
 
Distribution of intragastrically-administered [3H]-TG 
Mice were given an oral fat gavage (OFG) consisting of 20 μCi [3H]-labeled triolein 
(glycerol tri[9, 10(n)-3 H]oleate, 21.0Ci/mmol; Amersham Biosciences, 
Buckinghamshire, UK) in 150 μL of olive oil [24]. Mice were bled by cardiac puncture at 
1.5 hours. Serum and target tissues (liver, eWAT, heart, leg muscle and BAT) were 
collected after perfusion with NaCl solution 0.9%. Radiolabeled serum and tissue TG 
were separated from the FA using methanol:chloroform:heptane 1.4:1.25:1 (v:v:v) and 
0.1 mol/L H3BO3-KCO3 at pH 10.5. The radioactivity in the TG and FA fraction, in total 
serum and target tissues was determined by scintillation counting. 
 
Cardiomyocyte isolation 
Cardiomyocytes were obtained from the heart of our in vivo animal model by the 
Langendorff method. First, the heart was surgically removed and washed with a Ca2+ 
free Tyrode solution at 4ºC and oxygenated. The aorta was suspended in the 
Langendorff apparatus and the heart was perfused via the aorta with Ca2+ free Tyrode 
solution at 37ºC to clean blood remnants. The Ca2+ free Tyrode solution was then 
carefully removed, and the enzyme solution composed of Ca2+ free Tyrode solution 
with bovine serum albumin, collagenases and proteinases was added. Two reperfusion 
cycles (3 ml/min during 6 min) were performed to add the stop solution (Ca2+ free 
Tyrode solution without collagenases and proteinases). Once the perfusion was 
finished, the heart was removed from the Langendorff system and treated with an 
enzymatic solution for 5 min at 37ºC under shaking. The pieces of tissue were 
extracted with tweezers and, with shaking, submerged into stop solution to continue 
disaggregation. Tissue pieces were then removed and the solution containing the 
cardiomyocytes was centrifuged for 5 min at 450 rpm. The cell pellet was resuspended 




Frozen tissues (25 mg) (heart, liver, skeletal muscle, eWAT and BAT) were pulverized 
in liquid nitrogen using a mortar and a pestle. Samples were then homogenized in 
TriPureTM isolation reagent (Roche Molecular Systems) for total RNA and protein 














was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer’s 
instructions after the previous addition of Proteinase K. For RNA extraction from 
eWAT, the tissue was processed with the kit RNeasy Mini Kit (Qiagen). DNA was 
digested with DNase I (Invitrogen). Extracted RNA was eluted in 25 L of nuclease-free 
water. The yield and quality of RNA was tested by agarose electrophoresis and 
spectrophotometry. Isolated RNA was stored at –80C until use. 
 
LRP1-deficient cardiomyocyte cell culture 
Murine LRP1-deficient HL-1 cells were generated and kept in culture as previously 
described [9,10,25,26]. 
 
Hepatocyte (Hepa 1-6) cell culture 
Hepa 1-6 cells were cultured in DMEM supplemented with 10% FCS, 2 mmol/L L-
glutamine, 100 U/mL penicillin G, and 100 μg/mL streptomycin. Quiescent cells were 
used for two different experimental approaches. First, quiescent Hepa 1-6 were 
exposed to supernatants from LRP1- and LRP1- HL-1 cells. Second, quiescent Hepa 
1-6 were exposed to increasing dose of ANP (0 to 10 nM). 
Gene expression analyses by RT-PCR 
Total RNA (1 g) was used for cDNA synthesis according to the protocol provided with 
the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). cDNA was 
stored at –20C until its use. Gene expression analyses of Lrp1 (Mm00464608_m1), 
Vldlr (Rn01498166_m1), Ldlr (Mm01151339_m1), Cd36 (Mm01135198-m1), Nppa 
(Mm01255747_g1), Nppb (Mm01255770_g1), Cpt1 (Mm00550438), Fasn 
(Mm00662319_m1), Acaca (Mm01304257_m1), Acsl3 (Mm01255804_m1), Cav1 
(Mm00483057_m1), Slc27a2 (Mm00449517_m1) and Slc27a4 (Mm01327405_m1) 
were performed by quantitative real-time reverse transcriptase-polymerase chain 
reaction (q-RT-PCR) in the Applied Biosystems 7300 Real Time PCR System (Applied 
Biosystems; Foster City, CA, USA). 18srRNA (4319413E) was used as a 
housekeeping gene. The mRNA expression levels were measured in triplicate. The 
threshold cycle (Ct) values were normalized to the housekeeping gene. 
 
Proteomic studies 
Proteomic studies were performed as previously described with small modifications 
[27,28]. The mass spectrometry proteomics data have been deposited to the 














identifier PXD011564. The protein was digested with Sequencing Grade Modified 
Trypsin (Promega, Madison, WI, USA) using the FASP (Filter Aided Sample 
Preparation) digestion protocol as described [27]. A detailed description of the 
experimental procedures has been included in supplemental material. 
 
Immunoprecipitation Assays 
Dynabeads protein G was bound to the polyclonal anti-corin antibody (abcam 
ab125254) for 1 hour at room temperature. The protein extract was incubated with the 
Dynabeads Protein G-anti-corin complex overnight at 4°C. After incubation, the protein 
immune-complex beads were washed 3 times with the wash buffer and eluted with 50 
mM glycine. Samples were separated by SDS-PAGE and transferred blots were 
incubated with Ab against Serpin 1 (biorbyt orb319062). 
 
Corin catalytic activity assay. 
Protease corin activity was measured as previously described [29]. Corin activity was 
presented as Vmax. 
 
Immunoassays 
ANP (ab108797, Abcam), GDF-15 (MGD150, R&D Systems) and 
adrenalin/epinephrine (abx257158, Abbexa) plasma levels were measured by 
commercially available-enzyme-linked immunosorbent assays (ELISA), according to 
the manufacturer’s recommendations. 
 
Western blotting analysis 
Blots were incubated with antibodies against mouse LRP1 (β-chain, clone 5A6 RDI-
PRO61066), AMPK (Cell Signaling Technology, Inc, # 2532), pAMPK (Cell Signaling 
Technology, Inc, Thr172, 40H9, # 2535), pVASP (Santa Cruz Biotechnology, Inc, sc-
101439), BNP (Santa Cruz Biotechnology, Inc, sc-67455), ANP (Everest Biotech, 
EB11166), Serpin A1 (Biorbyt, orb319062), pACC (Cell Signaling Technology, 
1673661S, total ACC (Cell Signaling Techonology, 1673662S), pAkt (Cell Signaling 
Technology, #4060), total Akt (Cell Signaling Technology, #4685), UCP3 (Abcam, 
ab10985) and OXPHOS mitochondrial complexes (Abcam, ab110413). CPT1 from 
mitochondrial-enriched fractions in liver was determined [30] using the antibodies 
described by Herrero L et al [31] and registered in antibodyregistry.org (Dolors 














μg) were loaded, resolved on 12% SDS-PAGE and transferred to nitrocellulose 
membranes (BioRad). Signal detection was carried out with the ECL immunoblotting 
detection system (GE Healthcare) and the results were quantitatively analyzed using 
Chemidoc (BioRad). Equal protein loading in each lane was verified by incubating blots 
with monoclonal antibodies against troponin T (TnT) (Thermo Scientific #MS-295-P) or 
β-tubulin (Cell Signaling Technology, Inc, #2146). 
 
Measurement of cyclic GMP levels in tissues. 
The cyclic guanosine monophosphate (cGMP) levels in heart, liver and skeletal muscle 
were measured using an ELISA kit according to the manufacturer’s instructions for 
non-acetylated methodology (ADI-900-014, Enzo Life Sciences). 
 
Confocal microscopy  
Mouse heart cryosections were subjected to target ret ieval (10 mM Tris-HCl, pH=6) 
and permeabilized with Triton X-100 (0.5%). Isolated cardiomyocytes were fixed with 
paraformaldehyde and preserved in PBS with sodium acid 0.2%. Cells were 
permeabilized with glycine (0.1M) and Triton X-100 (0.2%). Samples were blocked with 
PBS, Tween-20 (0.2%) and BSA (1%) and incubated with primary antibody LRP1 (2 
µg/mL Abcam). Secondary antibodies conjugated with Alexa488 and Cy3 (1 ug/mL) 
(Jackson ImmunoResearch) were used for detection. Cell nuclei were counterstained 
with 4',6-diamidino-2-phenylindole (DAPI). Results were analyzed with an Axio-
Observer Z1 (Zeiss) laser confocal microscope. 
 
Histological staining 
Tissue samples were frozen and sectioned (5 μm). Sections were stained with 
Hematoxilin/Eosin, Herxheimer, Oil red O and Sirius red stains. Herxheimer and oil red 
O stainings were used for the detection of lipids. A polarized light microscope was used 
to measure collagen types I and III on randomly selected Sirius red-stained sections. 
 
Lipid extraction and semi-quantitative analysis of cholesteryl ester, free 
cholesterol, TG and FFA content in target tissues 
Frozen pulverized tissue (10 mg) were homogenized in NaOH 0.1 M. Lipids were 
extracted  and cholesteryl esters (CE), free cholesterol (FC) and TG content was 
analyzed by thin layer chromatography [9,10]. The FFA level was determined 















Determination of fatty acid β-oxidation (FAO) activity in target tissues  
Aliquots from heart and liver were homogenized in a buffer composed of 150 mM NaCl, 
1 mM dithiothreitol, 30 mM EDTA and 50 mM KH2PO4. Tissue fatty acid oxidation 
(FAO) was determined with 30 g of post nuclear supernatant by determining the 
conversion of palmitoyl CoA-1-14C into acetyl-CoA [32]. 
 
Indirect Calorymetry System 
Measurements of oxygen consumption (VO2) and CO2 production (VCO2) were 
performed using a comprehensive lab animal monitoring system (Oxymax-CLAMS, 
Columbus Instruments). Mice were acclimated in metabolic chambers for 1 day before 
the start of the recordings. Animals were continuously recorded for 2 days with 
measurements of their locomotor activity (in the xy and z axes) and gas exchange (O2 
and CO2) taken every 20 min. Energy expenditure was calculated according to 
manufacturer’s guidelines (Columbus Instruments). The respiratory quotient was 
estimated by calculating the ratio of CO2 production to O2 consumption. 
 
Statistical analysis 
Results are expressed as mean ± SEM. Differences between study groups were 
analyzed using one-way analysis of variance (ANOVA) followed by a post-hoc Tukey-b 
test, Student’s t-test for independent samples and Student’s t-test for paired samples. 
The statistical software R (www.r-project.org) was used for all statistical analyses. 
Differences were considered statistically significant when P < 0.050. 
 
3. Results 
3.1. Cardiomyocyte Lrp1 Deficiency Prevents Diet-Induced Overweight and 
Glucose Intolerance By Facilitating Increased Energy Expenditure  
Cardiomyocyte Lrp1 deficient (cm-Lrp1-/-) mice were generated as explained in section 
2.1 using the TnT-iCre transgenic mice provided by Zhou and Bu [20]. These authors 
showed that the transgenic method they used to generate TNT-iCre transgenic mice 
guarantees the deletion of genes exclusively in cardiomyocytes through all the states 
of heart development. Here, we investigated the effects of Lrp1 specific deletion in 
cardiomyocytes by crossing TnT-iCre transgenic mice with Lrp1flox/flox that generated 
cm-lrp1-/- mice. A schematic representation of cm-Lrp1-/- generation and genotyping is 














Lrp1 levels in isolated cardiomyocytes and in the heart (Figure 1C-E). However, not 
differences were found in other lipoprotein receptors including vldlr or ldlr in the heart of 
cm-Lrp1-/- and control mice (online Figure S2A). Lrp1 levels in liver, skeletal muscle and 
eWAT did not show differences between cm-Lrp1-/- and control mice (online Figure 
S2B-D).  
 
First, we evaluated the effects of cardiomyocyte-specific Cre deletor on Lrp1 
expression in chow-fed animals treated with doxycycline. These mice usually exhibit 
moderate increases in weight and IR when fed a chow diet, but sharp increases when 
fed a Western-type diet [22]. Surprisingly, the body weight of cm-Lrp1-/- mice was lower 
than that of the controls when the animals were fed a chow diet for a period of 6 weeks 
and this was concomitant with lower insulin levels and improved glucose tolerance as 
well as lower hepatic fat accumulation and eWAT weight (online Figure S3A-F). Thus, 
we used western diet-fed cm-Lrp1-/- mice to evaluate a putative role of cardiomyocyte 
Lrp1 deficiency on metabolic phenotype and the potential mechanisms involved. Lrp1 
deficiency did not cause significant alterations in functional or structural properties of 
the heart (online Figure S4 and S5) or in serum lipid profile (online Table S2). 
 
The body weight of cm-Lrp1-/- mice was lower than that of the controls at all tested 
times (Figure 2A) while the average weekly food intake was similar between both 
groups (online Figure S6). This suggests that the reduction in body weight gain was not 
due to differences of weekly food consumption. The weight-reducing effect of Lrp1 
deficiency was associated to decreased eWAT weight and eWAT/BAT adipocyte size 
(Figure 2A-C). While TG/FA content was reduced in the liver of cm-Lrp1-/- mice (Figure 
2D), no differences were found in the heart and skeletal muscle of both groups (online 
Figure S7). To know whether these phenotypic changes elicit a favorable metabolic 
profile, we conducted a TTG test. Compared with controls, cm-Lrp1-/- mice had lower 
glucose intolerance and lower AUC values (Figure 2E). Glucose, insulin and IR index 
(HOMA-IR) were reduced in cm-Lrp1-/- compared to control mice (Table 1). 
 
To determine whether cardiomyocyte Lrp1 deficiency reduces body weight and 
adiposity by regulating energy expenditure, we performed Comprehensive Lab Animal 
Monitoring System (CLAMS) experiments. These experiments showed that the 
ambulation activity was higher during the dark period than during the light period. 
There were, however, no differences between cm-Lrp1-/- and control mice (online 
Figure S8), indicating that the protection against weight gain of cm-Lrp1-/- mice was not 














during the light phase (Figure 3A) and higher glucose oxidation during the dark phase 
(Figure 3B). cm-Lrp1-/- mice showed higher VO2 and energy expenditure than controls 
during both phases (Figure 3C & D). 
 
3.2. Hearts with Lrp1 Deficiency Show Enhanced Corin Activity That Favors 
Higher ANP Release to the Plasma  
To identify cardiac proteins potentially involved in the favorable metabolic phenotype of 
cm-Lrp1-/- mice, we performed proteomic analysis of hearts from both cm-Lrp1-/- and 
cm-Lrp1+/+ mice groups. We processed three biological replicates from each group. 
Each replicate was a pool from three animals. We identified 24,358 spectra 
corresponding to 6,334 non-redundant peptides through a database search (1% FDR) 
(Data is available via the ProteomeXchange with the identifier PXD011564). For 
quantitative analysis, only peptides identified as unique (i.e. peptides sequences 
belonging to one single protein in the database) were considered. Overall, a total of 
1,213 proteins were quantified from 5,735 non-redundant unique peptides. Quantified 
proteins were compared between groups and we found a total of 34 differential 
expressed proteins. These 34 proteins included 11 which have the potential to be 
secreted (Table 2). Among the differential secreted proteins, we found atrial natriuretic 
peptide (ANP) (ratio=0.58; p=2.1E-04) and serine protease inhibitors including 
serpin1a (ratio=0.71; p=2.0E-12), serpin 1b (ratio=0.54; p=6.0E-05), serpin 1d 
(ratio=0.33; p=1.7-E-03) and serpin 3K (ratio=0.71; p=4.0E-09). To validate the 
Proteomics results, Western blot and immunoprecipitation experiments were 
performed. 
 
As shown in Figure 4A, ANP is generated from the precursor form proANP through the 
activation of corin, a convertase that facilitates the release of ANP (28 aa) from the C-
terminal end of proANP [33]. Western blot analysis performed with Abs that bind to the 
sequence RIGAQSGLGCNSFR at the C-terminal end of precursor form showed that 
proANP (14 kDa) levels were strongly decreased in cm-Lrp1-/- compared to control 
mice. This same test also showed preproANP (17 kDa) to be similar among the groups 
(Figure 4B). These results confirm proteomic differences (decreased levels of proANP 
in hearts from cm-Lrp1-/- mice) and suggest that there is higher release of ANP from 
LRP1- hearts. 
 
Immunoprecipitation studies evidenced that serpins form complexes with corin. The 
number of SerpinA1/Corin complexes were higher in the heart of cm-Lrp1-/- mice 














the heart of our murine model was 45-50 KDa and 30-35 KDa, which lines up with what 
was previously described of cultured cardiomyocytes [34]. Gladysheva IP et al reported 
that serpin1 binding to corin creates steric impediments to the union of effective 
inhibitors and allows prolonged corin activation [34]. 
 
Fluorogenic assays performed in this study revealed that protease enzymatic activities 
were higher in the cardiac membranes of Lrp1-/- mice with or without hirudin (Figure 
4D). Hirudin, a highly specific thrombin inhibitor, was added to the assay to exclude 
clotting enzymes in the membrane fraction. It did not show a significant effect on 
protease activity, suggesting that corin could be one of the main proteases contributing 
to the higher protease activity in cardiac membranes of Lrp1-/- mice.  
 
Circulating ANP levels were higher (about 4-fold) in the plasma of cm-Lrp1-/- than in 
that of cm-lrp1+/+ mice (Figure 4E). Our results suggest that cardiac Lrp1 deficiency 
facilitates corin activation and ANP release. There were no differences in cardiac Nppa 
between groups, whereas a modest downregulation in Nppb mRNA expression was 
found in cm-lrp1-/- mice (online Figure S9). No differences were found in the circulating 
levels of other metabolic factors including adrenalin/epinephrine and GFD15 (Figure 
4F,G). 
 
3.3. The ANP-NPR-A Signaling Activation Is Linked To AMPK Phosphorylation 
and Increased FA Oxidation in the Liver of cm-Lrp1-/- Mice  
To ascertain whether increased circulating ANP levels were associated with the 
activation of NPR-A signaling in peripheral tissues, we determined the levels of crucial 
mediators such as cGMP and pVASP in the liver, skeletal muscle and heart of cm-
Lrp1+/+ and cm-Lrp1-/- mice whether treated with the NPR-A antagonist A71915 or not 
(online Figure S1B). cGMP and VASP were increased in the liver (Figure 5A,B) and 
skeletal muscle (online Figure S10A,B) but not the heart (online Figure S11A,B) of 
untreated cm-Lrp1-/- mice. The treatment of cm-Lrp1-/- mice with A71915 completely 
blocked the increase of cGMP and pVASP levels in liver and partially blocked it in 
skeletal muscle. We found that cGMP/pVASP signaling was linked to increased AMPK 
phosphorylation in the liver. Increased levels of hepatic pAMPK, like those of cGMP 
and pVASP, were abolished by the NPR-A antagonist (Figure 5A,B). There were no 
differences in pAMPK levels in the skeletal muscle (online Figure S10B) or the heart 
(online Figure S11B) between groups. To know whether AMPK phosphorylation was 
linked to AMPK activity, we measured the phosphorylation of ACC, the downstream 














extremely low (reduced by aprox. 90% in HFD fed mice). Despite this, we detected an 
increased ratio pACC/total ACC in the liver of untreated cm-Lrp1-/- compared to the 
control mice (Figure 5A). In addition, the increase in the phosphorylation of ACC was 
not observed in A91915-treated mice, supporting the activation of AMPK by ANP in the 
liver of KO mice. To explore the potential impact of pAMPK activation on hepatic FA 
synthesis, we explored several genes involved in FA synthesis in the liver. We found 
that Acsl3 mRNA expression was significantly lower in the liver of KO mice compared 
to the controls (online Figure S12). There were no differences in the mRNA expression 
levels of Fasn or Slc27a2 between groups. 
 
To know the impact of pAMPK on FAO, we measured CPT1, a key mitochondrial 
enzyme responsible for FAO; the main components of the oxidative phosphorylation 
system (OXPHOS), responsible for mitochondrial respiration; and UCP3, an indicator 
of mitochondrial response to enhanced intracellular FA. Oxidative phosphorylation 
involves a flow of electrons through the electron transport chain (ETC), a series of 
proteins and electron carriers within the mitochondrial membrane. We used one 
OXPHOS cocktail antibody that contains 5 mouse Abs and detects one subunit of each 
(five) mitochondrial complexes of the ETC. The main subunits detected in whole 
hepatic and skeletal muscle tissue extracts of our murine model were CV-ATP5A (55 
kDa), CIII-UQCRC2 (48 kDa) and CII-SDHB (30 kDa). The protein levels of CPT1, CII, 
and CV subunits of ETC were significantly higher in the liver (Figure 5C) of untreated 
KO mice. The increase in these mitochondrial proteins was abolished in cm-Lrp1-/- mice 
treated with A71915, indicating that NPRA-signaling is involved in the increase of 
OXPHOS protein subunits in mice. UCP-3, an indicator of FA supply to mitochondria, 
was also induced in the liver (Figure 5C) but not in the skeletal muscle (online Figure 
S10C) of KO mice. These results suggest that, despite the upregulatory effect of ANP 
signaling on OXPHOS subunits of the skeletal muscle, ANP signaling is not linked to 
FA oxidation in the skeletal muscle. 
 
According to CPT1 upregulation, the hepatic FAO activity was higher in untreated KO 
mice than in control mice, but this increase was not observed in KO mice treated with 
A71915 (Figure 5D). In addition, KO mice showed reduced hepatic TG accumulation in 
the untreated mice but not in the A71915–treated mice (Figure 5E). 
 
To explore whether these favorable changes may influence insulin signaling activation, 
we measured the activation state of Akt in different tissues. We found an increased 















3.4. Supernatants from LRP1 deficient HL-1 Cells Increased pAMPK and CPT1 
Levels in Cultured Hepatocytes 
LRP1-deficient HL-1 cells (LRP1-) were generated in our group and previously used to 
test the impact of the cardiomyocyte LRP1 deficiency in several processes 
[9,10,25,26]. LRP1- cells show almost undetectable levels of LRP1 but similar 
morphologic characteristics to the control cells (Figure 6A,B). Supernatants from LRP1- 
cells contain higher ANP levels than those from control cells (Figure 6C), and, when 
added to hepatocytes, caused induced AMPK phosphorylation and increased CPT1 
protein levels in cultured Hepa 1-6 cells (Figure 6D,E). In parallel experiments, we also 
showed that ANP from 0 to 10 nM caused an increase in pAMPK/AMPK ratio and 
CPT1 protein levels in a dose-response manner without altering cell morphology 
(online Figure S14A-C). 
 
3.5. Activated ANP-NPR-A Signaling Is Linked to Increased FA Uptake by the 
Liver 
AMPK phosphorylation has been previously reported to activate FA uptake in oxidative 
tissues [35,36]. Oral fat gavage (OFG) experiments showed an increase in 3H-TG and 

3H-FFA uptake by the liver of cm-Lrp1-/- mice that was blocked by the NPR-A 
antagonist A71915 (Figure 7A). Real-time PCR experiments showed an increased 
expression of hepatic Vldlr and Cd36 mRNA in cm-Lrp1-/- mice (Figure 7C) that were 
also efficiently blocked by the NPR-A antagonist. Unlike the liver, there were no 
differences between KO and control mice in 3H-TG and 3H-FFA uptake by the 
skeletal muscle, although a significant increase in 3H-TG and 3H-FFA uptake was 
detected in groups treated with A71915 (online Figure S15). In contrast to liver, there 
was a reduced uptake of 3H-TG and 3H-FFA by eWAT of cm-Lrp1-/- mice (Figure 
7B). Reduced levels of Vldlr and Cd36 mRNA expresion was detected in eWAT of KO 
versus control mice (Figure 7D). As shown in Figure 7E,F, A71915 equaled eWAT 
weight and eWAT adipocyte size between cm-Lrp1-/- and cm-Lrp1+/+ mice. 
 
CLAMS experiments showed that treatment of cm-Lrp1-/- mice with the NPR-A 
antagonist counteracted increased lipid oxidation during the light phase (Figure 8A) 
and increased glucose oxidation during the dark phase (Figure 8B). There were no 
differences in oxygen consumption (Figure 8C) and energy expenditure (Figure 8D) 
















The main innovative findings of this study are that LRP1 receptor levels in 
cardiomyocytes regulate circulating levels of atrial natriuretic peptide and that through 
this mechanism control NPRA-dependent fatty acid metabolism in the liver and, 
consequently, the whole-body metabolism. 
LRP1 Controls the Systemic Levels of Atrial Natriuretic Peptide through 
Modulation of Corin Activity in Cardiomyocytes 
Here, we show that isolated cardiomyocytes from cm-Lrp1-/- mice are deficient in the 
receptor Lrp1. Previous studies have shown that LRP1 plays a crucial role in the 
degradation of serpin:protease complexes [37,38]. Results from the 
immunoprecipitation assays performed in this study indicated that corin, the main 
protease responsible for cardiac release of atrial natriuretic peptide [33], was mostly 
complexed with serpins in the heart of cm-Lrp1-/- mice, as it was previously shown in 
cultured cardiomyocytes [34]. In agreement with the capacity of LRP1 to modulate 
protease levels, we found that Lrp1 deficiency in the cardiomyocyte, the most abundant 
and main ANP producing cell in the heart [39,40], directly impacts corin activity, cardiac 
ANP release and ANP circulating levels. A more direct proof of the capacity of LRP1 to 
modulate ANP release has been obtained from cell culture experiments performed with 
an LRP1-deficient HL-1 cell line (LRP1- HL-1 cells) previously generated in our group 
[9,10,25,26]. Our results evidenced the presence of higher ANP levels in the 
supernatants from LRP1- HL-1 cells compared to control cells. 
The protease corin is also involved in the cleavage of pro-brain natriuretic peptide 
(BNP) to BNP [41]. Despite this, we did not observe alterations in cardiac or plasma 
BNP levels in cm-Lrp1-/- mice compared to the controls. The specific effect of the 
receptor deficiency on ANP release could be explained by the predominance of ANP 
(compared to the marginal presence of BNP) in hearts without ventricular dysfunction 
[42]. 
 
Several groups including ours, have determined that the modulation of Lrp1 receptor 
causes alterations of key signaling pathways in the heart. Our group reported that 
cardiac Lrp1 overexpression contributes to enhanced cholesterol and triglyceride 
supply to the heart and is associated with serious calcium-handling alterations [25]. In 
the context of the myocardial infarction, LRP1 signaling activation has been reported to 
induce a cardioprotective signal, decreases infarct size, and preserves cardiac systolic 
function in young adult mice without comorbidities [43]. Elevated levels of Lrp1 ligands, 














study show that cardiomyocyte Lrp1 deficiency did not affect in cardiac function. This 
could be related to the absence of pathological stressors such as atherogenic 
dyslipemia or hypoxia. Further studies are required to know the optimal Lrp1 threshold 
values in the presence of certain pathological ligands  
 
ANP Activates NPR-A Signaling That Is Linked to AMPK Phosphorylation and 
Increased FA Oxidation/FA Uptake in the Liver of cm-Lrp1-/- Mice.  
The systemic effects of ANP are well described, contributing to water-salt balance 
maintenance and blood pressure regulation through diuretic, natriuretic and 
vasodilatory effects. In addition, ANP displays important pleiotropic effects in the heart, 
acting as a main regulator of cardiovascular homeostasis in an autocrine and paracrine 
manner [45]. Besides the hemodynamic effects, ANP also is involved in lipolytic 
processes in white adipose tissue in primates [46]. Recently, it has been described as 
a potent lipolytic agent that exerts a great impact on the metabolism of patients with 
heart failure [47]. Interestingly, ANP induces anti-inflammatory effects in adipose tissue 
[48].  
 
ANP has also been reported to promote oxidative metabolism in human skeletal 
muscle. In particular, ANP induces PGC-1α and mitochondrial OXPHOS gene 
expression in a cyclic GMP–dependent manner in human myotubes [49]. Results from 
the present study show that ANP increased NPR-A/cGMP/pVASP in the skeletal 
muscle of cm-Lrp1-/- mice. In our murine model, this upregulatory effect of ANP 
signaling was linked to mitochondrial OXPHOS upregulation, affecting CV-ATP5A and 
CII-SDHB subunit overexpression. However, there were no differences in the levels of 
phosphorylated AMPK, the TG/FA uptake, the levels of CPT1 and UCP3, and TG 
accumulation in the skeletal muscle of cm-Lrp1-/- and control mice. These results 
indicate that FA uptake and FA oxidation were not significantly modulated by NPR-
A/cGMP/pVASP signaling in the skeletal muscle of cm-Lrp1-/- mice. 
 
In contrast, we found that NPR-A/cGMP/pVASP signaling was linked to AMPK 
phosphorylation in the liver of cm-Lrp1-/- mice. Our cell culture experiments evidenced 
that hepatocytes exposed to supernatants from LRP1- HL-1 cells or to ANP directly 
showed increased levels of phosphorylated AMPK. Previous studies have shown that 
pVASP, an ANP signaling mediator, phosphorylated specifically AMPK in the liver of a 
mouse model of diabetes [50]. AMPK is considered the master regulator of lipid 
metabolism and mitochondrial homeostasis [51–54]. One of the crucial functions of 














activation of AMPK, phosphorylation of ACC results in ACC inactivation. Our results 
indicate that ACC phosphorylation is increased in the liver of KO mice and abolished 
by the treatment of KO mice with the NPR-A antagonist, indicating that the energy 
sensing AMPK/ACC pathway can be modulated by ANP in the liver. Acsl3 mRNA 
expression levels were also decreased in the liver of cm-Lrp1-/- compared to control 
mice. Acsl3 knockdown decreased total acyl-CoA synthetase activity in ob/ob mice and 
mice fed a high sucrose diet [55]. Together, these results support that ANP-induced 
AMPK phosphorylation is involved in the deactivation of FA synthesis in the liver of cm-
Lrp1-/- mice.  
 
The phosphorylation of ACC inhibits the production of malonyl-CoA, a substrate for 
fatty acid synthase (FAS) and a potent inhibitor of CPT1 [56]. CPT1 is the main 
mitochondrial enzyme responsible for fatty acid oxidation. Results from the present 
study showed increased levels of CPT1 in the liver cm-Lrp1-/- mice and in hepatocytes 
exposed to increased ANP levels. We also showed that this increase in dependent of 
NPR-A signaling. The link between AMPK phosphorylation and CPT1 activation has 
been previously shown in oxidative tissues of a mice model [36,51]. The upregulation 
of the mitochondrial OXPHOS subunits support and enhanced mitochondrial 
respiration in the liver of cm-Lrp1-/- mice. Further experiments are required to know the 
mechanism by which ANP signaling enhances the level of these OXPHOS protein 
subunits. This could be due to enhanced mitochondrial synthesis or enhanced amount 
of protein subunits per mitochondria. Together these results support an ANP-enhanced 
mitochondrial fatty acid oxidation in the liver of cm-Lrp1-/- mice.  
 
Finally, UCP3, an indicator of mitochondrial response to intracellular FA, 3H-FA and 

3H-TG uptake and FA/TG transporters such as Cd36 and VLDLR were upregulated in 
the liver of KO mice and the increase was abolished by the treatment of KO mice with 
the NPR-A antagonist. Previous studies have reported that pAMPK positively 
modulates Cd36 in a mouse model of AMPK activation specifically in the liver [57].  
Together, these results evidenced that ANP signaling promoted by cardiomyocyte 
LRP1 deficiency facilitates the repression of FA synthesis and the activation of FA 
uptake/FA mitochondrial oxidation in an AMPK-coordinated manner in the liver of cm-
Lrp1-/- mice. 
 















Here, we show that enhanced FA uptake and oxidation promoted by ANP reduces TG 
accumulation in the liver of KO mice. These results are in agreement with previous 
studies showing that moderate increases in Cpt1a activity are sufficient to reduce 
hepatic TG levels in CPT-1a-overexpressing animals [58] and even to modulate 
diabetes and obesity [30]. Interestingly, reduced hepatic triglyceride content in KO mice 
occurred in the context of enhanced supply of FA to the liver, and, by counteracting 
ANP-induced FA uptake by the liver, the NPR-A antagonist caused an increased FA 
uptake by eWAT. Although, a direct effect of ANP on adipose tissue of cm-Lrp1-/- 
cannot be discarded, data from the present study supports the secondary nature of 
cardiac Lrp1 deficiency’s benefits such as reducing diet-induced obesity and increasing 
energy expenditure. The liver is considered the main organ in the homeostasis of lipids 
and glucose and one of the highest contributors to whole-body lipid oxidation [59]. 
Moreover, previous studies have consistently demonstrated the link between the 
hepatic FAO and insulin-resistance [45,47,54]. Results from the present study show 
that phosphorylation of Akt, a crucial step in the insulin signaling pathway, is more 
active in the liver of cm-Lrp1-/- mice compared with controls. In addition, CLAMS 
experiments showed an ANP-induced glucose oxidation during the dark phase. 
However, further studies based on the analysis of signaling right after insulin 
administration are indeed required to obtain conclusions about the role of ANP on the 
modulation of diet-induced hepatic insulin resistance [60]. Similarly, it would be 
interesting to determine whether the response to leptin is altered in our model. 
 
Main Conclusions and Translational Potential of the Work  
Our results show that the favorable metabolic profile and increased energy expenditure 
in cm-Lrp1-/- mice mainly depends on ANP signaling involving hepatic AMPK activation 
(summarized in Figure 9). 
From the clinical point of view, our team has evaluated natriuretic peptide levels in 
patients with chronic heart failure. Recently, we described that patients with a low 
capacity to degrade active natriuretic peptides had better outcomes [61,62]. In humans, 
the main protective metabolic effects of ANP are related to ANP lipolytic effects in 
adipose tissue [46,63–67]. In fact, high levels of natriuretic peptides in plasma have 
been associated with weight loss in humans [66,67]. Here, treatment of cm-Lrp1-/- mice 
with the NPR-A antagonist restores energy expenditure to the levels of control mice, 
suggesting that ANP/NPR-A signaling is involved in the increased energy expenditure 
and reduced weight of cm-Lrp1-/- mice. It will be interesting to test in humans whether 
ANP-induced hepatic FA uptake/oxidation is an additional mechanism contributing to 














low levels of Lrp1 expression in cardiomyocytes would contribute to the maintenance of 
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Figure 1. cm-Lrp1-/- Transgenic Mice Generation and Validation 
(A) Generation schedule of an in vivo model with a doxycycline-inducible attenuation of 
Lrp1 expression selectively in cardiomyocytes. In cm-Lrp1-/- mice with the genotype 
TnTCre+/+ Lrp1flox/flox, the activation of Cre recombinase by doxycycline converts the 
Lrp1 floxed alleles to KO (-) alleles. (B) Cre and Flox transgens were detected by PCR. 
A fragment of 500 bp was amplified from mouse tail genomic DNA when the Cre 
transgene driven by the TnT promoter was present. A fragment of 350 bp was 
amplified when flox sequences flank lrp1 gen. (C) Ten-week-old male mice were 
treated daily with doxycycline cyclate through their drinking water during the procedure 
to assess the conditional inhibition of LRP1 levels in cardiomyocytes. After three days 
of treatment, both cm-Lrp1+/+ and cm-Lrp1-/- mice were randomized and fed a chow diet 
or high fat diet for six weeks. (D) Lrp1 mRNA expression and LRP1 protein levels (in 
green) in isolated cardiomyocytes from hearts of cm-Lrp1-/- and control mice (E) Lrp1 
mRNA expression and LRP1 protein levels (LRP1 staining in red, nuclei in blue, 
Bar=20 m) in the heart. Data represent the mean±SEM for 9 mice per group. *** 
p<0.005 versus cm-Lrp1+/+ mice; ### p<0.005 versus chow diet. Differences between 
groups were analyzed using one-way analysis of variance (ANOVA) followed by a 















Figure 2. Lrp1 Deficiency in Cardiomyocytes Improves Diet-induced Glucose 
Intolerance and Reduces Weight Gain 
cm-Lrp1+/+ and cm-Lrp1-/- mice (control) mice were treated for 6 weeks with doxycycline 
cyclate in their drinking water. (A) Body weight changes over 6 weeks of HFD diet. (B) 
Epididymal white adipose tissue (eWAT) tissue mass at necropsy. (C) Representative 
H&E stained sections from eWAT and brown adipose tissue (BAT) (Bar=100 m). (D) 
Triglyceride and FA content in the liver and representative Herxheimer stained liver 
sections (Bar =100 μm). (E) Glucose tolerance test in mice (1.3 mg/g body weight) and 
Area under the curve (AUC). The data represents the mean±SEM. n=9 mice per 
condition. **p<0.01 or *** p<0.005 versus control mice. Differences between groups 
were analyzed using Student’s t test for independent samples. 
 
Figure 3. Cardiomyocyte Lrp1 Deficiency Increases Whole-Body Energy 
Consumption 
cm-Lrp1+/+ and cm-Lrp1-/- mice (control) mice were treated for 6 weeks with doxycycline 
cyclate in their drinking water and then submitted to CLAMS experiments. Oxymax 
respirometer measurements of lipid oxidation (A), glucose oxidation (B), VO2 (C) and 
whole-body oxygen consumption (D) during the light and dark periods in mice over 6 
weeks on HFD. n=8 mice per condition.  *p<0.05, **p<0.01 or ***p<0.005 versus cm-
Lrp1+/+ mice. Differences between groups were analyzed using Student’s t test for 
independent samples. 
 
Figure 4. Cardiomyocyte Lrp1 Deficiency Favors Higher Corin Activity and ANP 
Release 
 (A) Schematic representation for the secretion of preproANP-derived peptides 
modified from Pemberton et al [23]. The AA sequence RIGAQSGLGCNSFR that is 
recognized by the antibody (Ab) is localized at the extreme C-terminal of the protein. 
cm-Lrp1+/+ and cm-Lrp1-/- mice (control) mice were treated for 6 weeks with doxycycline 
cyclate in their drinking water. After sacrifice, one aliquote of frozen heart tissue was 
used for protein extraction. (B) Representative Western blot analysis showing cardiac 
preproANP (16 kDa), proANP (13 kDa) and troponin (TnT) (endogenous control) 
protein bands and bar graphs showing the quantification of preproANP and proANP 
protein bands normalized to TnT. One aliquot of cardiac membranes (5 mg) was used 
for immunoprecipitation with anti-corin Abs. (C) Immunoblots performed with anti-
SerpinA1 Abs showing two different molecular weight corin/serpinA1 complexes and 














(D) Other aliquot of cardiac membranes (25 µg) was used for membrane protease 
catalytic activity measurements (Vmax) in absence or presence of the thrombin 
inhibitor hirudin (2 µM). (E-G) Circulating levels of ANP, adrenalin/epinephrine and 
GDF15 measured by ELISA. n=6 mice per condition. Data represent the mean±SEM. 
**p<0.01 or ***p<0.005 versus cm-Lrp1+/+ mice. Differences between groups were 
analyzed using Student’s t test for independent samples. 
 
Figure 5. High Plasma ANP Levels in cm-Lrp1-/- Mice Induce NPRA-Dependent 
Signaling Linked to AMPK Phosphorylation and Increased Fatty Acid Oxidation 
in the Liver 
cm-Lrp1+/+ and cm-Lrp1-/- mice (control) mice were treated for 6 weeks with doxycycline 
cyclate in their drinking water and then treated with either saline or the NPRA 
antagonist A71915 (200 µg/kg in PBS in a final volume of 100 µl) for the last 4 weeks. 
(A) cGMP levels were detected by ELISA. Western blot analysis and bar graphs 
showing the quantification of pVASP, total VASP, pAMPK, total AMPK, pACC and total 
ACC (B) and OXPHOS, UCP3 and CPT1 (C) in the liver. (D)  Rate of hepatic fatty acid 
oxidation (FAO). (E) Representative Herxheimer stained liver sections (Bar =100 µm) 
and hepatic TG levels. n=8-10 mice per condition. Data represent the mean±SEM. 
*p<0.05, ** p<0.01 or *** p<0.005 versus cm-Lrp1+/+ mice; ## p<0.01 or ### p<0.005 vs 
PBS. Differences between groups were analyzed using one-way analysis of variance 
(ANOVA) followed by a post-hoc Tukey-b test. 
 
Figure 6. Hepatocytes Exposed to Supernatants from LRP1-deficient (LRP1-) HL-
1 Cardiomyocytes Exhibited Increased Levels of Phosphorylated AMPK and 
CPT1  
LRP1 deficient HL-1 (LRP1-) and control HL-1 cells (LRP1+) were grown in complete 
Claycomb medium from 48 hours and supernatants were then collected. After 
determination of their ANP content by ELISA, supernatants were directly added to 
cultured hepatocytes (Hepa 1-6). Hepa 1-6 were exposed to HL-1 supernatants for 18 
hours and then collected in lysis buffer to perform Western blot analysis. (A) 
Representative optical microscopy image of LRP1+ and LRP1- HL-1 cells. (B) Western 
blot analysis and bar graphs showing LRP1 protein levels in LRP1- compared to 
LRP1+ HL-1 cells. (C) ANP levels in LRP1+ and LRP1- supernatants measured by 
ELISA. (D) Representative optical microscopy image of Hepa 1-6 cells exposed to 
supernatants from LRP1+ and LRP1- HL-1 cells. (E) Western blot analysis and bar 














represent the mean±SEM of three experiments performed in duplicate. ** p<0.01 or *** 
p<0.005 versus LRP1+ HL-1 cells or versus Hepa 1-6 cells exposed to supernatants 
from control HL-1 cells. Differences between groups were analyzed using Student’s t 
test for independent samples. 
 
Figure 7. TG and FA Uptake Increased in the Liver while Decreased in eWAT of 
cm-Lrp1-/- Mice 
cm-Lrp1+/+ and cm-Lrp1-/- mice (control) mice were treated for 6 weeks with doxycycline 
cyclate in their drinking water and then treated with either saline or the NPRA 
antagonist A71915 for the last 4 weeks. Mice were then given an oral fat gavage 
(OFG) consisting of 20 μCi [3H]-labeled triolein in 150 μL of olive oil as. Percentage of 
[3H]-triglyceride and [3H]-free fatty acid uptake by liver (A) and eWAT (B) in the different 
groups taking as reference the control group.  Real-time PCR of Vldlr and Cd36 mRNA 
expression levels in liver (C) and eWAT (D). (E) Representative Herxheimer stained 
eWAT sections (Bar =100 µm). Data represent the mean±SEM. *p<0.05, **p<0.01 or 
***p<0.005 versus control mice; ## p<0.01 or ### p<0.005 versus PBS. Differences 
between groups were analyzed using one-way analysis of variance (ANOVA) followed 
by a post-hoc Tukey-b test. 
 
Figure 8. Cardiomyocyte Lrp1 Deficiency Increases Whole-Body Energy 
Consumption in an NPR-A Dependent manner 
cm-Lrp1+/+ and cm-Lrp1-/- mice (control) mice were treated for 6 weeks with doxycycline 
cyclate in their drinking water and then treated with either saline or the NPR-A 
antagonist A71915 for the last 4 weeks. Oxymax respirometer measurements of lipid 
oxidation (A), glucose oxidation (B) VO2 (C) and whole-body oxygen consumption (D) 
during the light and dark periods. n=8-10 mice per condition.  *p<0.05, ** p<0.01 or 
***p<0.005 versus control mice; ## p<0.01 or ### p<0.005 versus PBS. Differences 
between groups were analyzed using one-way analysis of variance (ANOVA) followed 
by a post-hoc Tukey-b test. 
 
Figure 9. Schematic main figure 
Cardiomyocyte Lrp1 deficiency facilitates corin activation and ANP release from the 
heart. NPR-A/cGMP/pVASP signaling activates AMPK/ACC pathway that coordinately 
inhibits FA synthesis and activates FA uptake and oxidation in the liver of cm-Lrp1-/- 














hepatic TG content, the improved glucose tolerance, the limited weight gain and the 
enhanced whole-body energy consumption of cardiomyocyte-lrp1 deficient mice.  
 
Table 1. Comparison of serum glucose levels, serum insulin levels and Homeostatic Model 
Assessment for Insulin Resistance (HOMA-IR) between cm-Lrp1
-/-
 and control mice. The data is 
shown as mean±SEM. N=8 per group. Differences between groups were analyzed using the Student’s t 








GLUCOSE (mM) 11.09 ± 0.37 9.49 ± 0.84 0.072 
INSULIN (g/L) 1.23 ± 0.17 0.48 ± 0.04 0.003 









 mice. This table 
shows mass spectromic proteomic data concerning differential cardiac secreted proteins. Three biological 
replicates for each condition were processed. Each replicate was a pool of tissue obtained from three 
different animals. Differences between groups were analyzed using Student’s t test for 
independent samples.  
 







E9PV24 Fibrinogen alpha chain  Fga 0.64 1.8E-12 
P05125 Natriuretic peptides A (ANP) Nppa Pnd 0.57 4.8E-04 
P07759 Serine protease inhibitor A3K Serpina3k Mcm2 Spi2 0.63 1.6E-12 
P22599 Alpha-1-antitrypsin 1-2  Serpina1b Aat2 Dom2 Spi1-2 0.44 1.2E-05 
Q00897 Alpha-1-antitrypsin 1-4  Serpina1d Dom4 Spi1-4 0.30 9.4E-04 
Q3TFQ8 Alpha-1,4 glucan phosphorylase Pygb 0.72 8.1E-16 
Q6S9I0 Kininogen Kng2 0.77 1.1E-03 
P01942 Hemoglobin subunit alpha Hba 0.74 9.6E-05 
Q8K0E8 Fibrinogen beta chain Fgb 0.66 6.6E-14 
Q8VCM7 Fibrinogen gamma chain Fgg 0.65 5.5E-08 
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 Cardiomyocyte Lrp1 deficiency preserves corin activity and promotes ANP 
release 
  
 Increased blood ANP levels activate cGMP/pVASP axis in skeletal muscle 
and liver  
 
 In the liver, but not in skeletal muscle, cGMP/pVASP axis was linked to 
AMPK phosphorylation and activation 
 
 Increased hepatic pAMPK promotes whole-body systemic energy 
expenditure 
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